BTIG Research began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO) in a research report released on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $49.00 price objective on the stock.

Other equities research analysts have also issued reports about the company. HC Wainwright began coverage on BridgeBio Pharma in a research note on Monday, April 13th. They set a buy rating and a $50.00 price objective for the company. Zacks Investment Research cut BridgeBio Pharma from a buy rating to a hold rating in a research report on Monday, May 18th. Mizuho began coverage on BridgeBio Pharma in a research report on Tuesday, February 18th. They issued a buy rating and a $51.00 target price for the company. ValuEngine raised BridgeBio Pharma from a hold rating to a buy rating in a research report on Friday, May 1st. Finally, BidaskClub raised BridgeBio Pharma from a sell rating to a hold rating in a research report on Friday, April 24th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $44.09.

BBIO opened at $34.73 on Tuesday. The firm has a market cap of $4.22 billion and a PE ratio of -14.00. The company has a quick ratio of 14.25, a current ratio of 14.25 and a debt-to-equity ratio of 1.03. The business has a fifty day simple moving average of $29.53 and a 200-day simple moving average of $31.28. BridgeBio Pharma has a fifty-two week low of $14.23 and a fifty-two week high of $48.36.

BridgeBio Pharma (NASDAQ:BBIO) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.09). On average, equities research analysts anticipate that BridgeBio Pharma will post -3.03 EPS for the current fiscal year.

In related news, insider Brian C. Stephenson sold 1,494 shares of BridgeBio Pharma stock in a transaction on Monday, May 4th. The stock was sold at an average price of $30.00, for a total transaction of $44,820.00. Following the completion of the sale, the insider now owns 324,316 shares of the company’s stock, valued at $9,729,480. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Neil Kumar sold 79,600 shares of the firm’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $31.02, for a total value of $2,469,192.00. Following the transaction, the chief executive officer now owns 4,685,725 shares in the company, valued at $145,351,189.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 165,101 shares of company stock valued at $4,759,159.

A number of hedge funds and other institutional investors have recently bought and sold shares of BBIO. Janus Henderson Group PLC raised its holdings in BridgeBio Pharma by 594.7% during the fourth quarter. Janus Henderson Group PLC now owns 3,141,081 shares of the company’s stock valued at $110,095,000 after buying an additional 2,688,910 shares in the last quarter. BlackRock Inc. raised its holdings in BridgeBio Pharma by 96.4% during the first quarter. BlackRock Inc. now owns 5,222,598 shares of the company’s stock valued at $151,457,000 after buying an additional 2,562,875 shares in the last quarter. State Street Corp raised its holdings in BridgeBio Pharma by 112.0% during the first quarter. State Street Corp now owns 1,713,716 shares of the company’s stock valued at $49,698,000 after buying an additional 905,473 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in BridgeBio Pharma by 513.7% during the fourth quarter. Nuveen Asset Management LLC now owns 536,163 shares of the company’s stock valued at $18,793,000 after buying an additional 448,791 shares in the last quarter. Finally, Cormorant Asset Management LP raised its holdings in BridgeBio Pharma by 17.4% during the first quarter. Cormorant Asset Management LP now owns 2,950,000 shares of the company’s stock valued at $85,550,000 after buying an additional 437,135 shares in the last quarter. Institutional investors own 91.28% of the company’s stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Recommended Story: Short Selling

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.